Minerva Neurosciences, Inc.

NERV

Explore Our Financial Data > Companies > Micro Cap > Minerva Neurosciences, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
NERV
CIK0001598646
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address1601 TRAPELO ROAD, SUITE 286, WALTHAM, MA, 02451
Website minervaneurosciences.com
Phone617-600-7373
CEORémy H. Luthringer
Employees9

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$0.00
Pre-Tax Income$-293.37 million
Net Income$-293.42 million
Net Income to Common$-293.42 million
EPS$-34.67
View All
Balance Sheet
Cash$82.30 million
Assets$97.97 million
Liabilities$233.76 million
Common Equity$-140.75 million
Liabilities & Equity$97.97 million
View All
Cash Flow Statement
Net Income$-293.42 million
Cash From Operating Activities$-13.51 million
Cash From Investing Activities$0.00
Cash From Financing Activities$74.45 million
Change in Cash$60.94 million
View All
Calculations
NOPAT$-10.57 million
EBITDA$-294.31 million
Price to EarningsN/A
Price to BookN/A
ROEN/A
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences

Key market opportunities in NRG Fusion include developing targeted therapies for rare NRG1 fusions in cancers like NSCLC and pancreatic cancer. Despite low prevalence, these oncogenic drivers offer growth potential, especially in China. Emerging therapies like Zenocutuzumab and HMBD-001 in clinical trials further the market scope.Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "NRG Fusion - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report delivers in-de

Article Link

Minerva Announces Leadership Transition

Jim O’Connor joins as Chief Business Officer and General CounselBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O’Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company’s President, has elected to leave the company. Mr

Article Link

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the first patient has been screened in its globa

Article Link

Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of

Article Link

Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms

Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of schizophrenia—an area where management has historically lagged behind treatments for positive sympto

Article Link